Amplia Therapeutics Reports Strong Clinical Results and Maintains Solid Funding Position
Amplia Therapeutics Limited (ASX: ATX) recorded meaningful progress in the March 2026 quarter, supported by positive clinical outcomes for narmafotinib. The ACCENT trial delivered strong efficacy, including five complete responses, an objective response rate of 35.9%, and median overall survival of 11.1 months, exceeding historical benchmarks. The drug also showed good tolerability. The company completed large-scale GMP manufacturing of ~13 kg of narmafotinib, strengthening readiness for late-stage trials. Preclinical data further highlighted improved outcomes when combined with kRAS inhibitors. However, the AMPLICITY trial halted recruitment due to chemotherapy-related toxicity, not linked to narmafotinib. Financially, Amplia ended the quarter with AU$27.9 million in cash, with operating cash outflows of AU$3.5 million, primarily driven by research and development spending of AU$2.8 million. The company has an estimated funding runway of 7.9 quarters, supporting ongoing clinical development and regulatory planning.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Amplia Therapeutics Reports Strong Clinical Results and Maintains Solid Funding Position
Amplia Therapeutics Limited (ASX: ATX) recorded meaningful progress in the March 2026 quarter, supported by positive clinical outcomes for narmafotinib. The ACCENT trial delivered strong efficacy, including five complete responses, an objective response rate of 35.9%, and median overall survival of 11.1 months, exceeding historical benchmarks. The drug also showed good tolerability. The company completed large-scale GMP manufacturing of ~13 kg of narmafotinib, strengthening readiness for late-stage trials. Preclinical data further highlighted improved outcomes when combined with kRAS inhibitors. However, the AMPLICITY trial halted recruitment due to chemotherapy-related toxicity, not linked to narmafotinib. Financially, Amplia ended the quarter with AU$27.9 million in cash, with operating cash outflows of AU$3.5 million, primarily driven by research and development spending of AU$2.8 million. The company has an estimated funding runway of 7.9 quarters, supporting ongoing clinical development and regulatory planning.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au